Mukherjee C, Caron M G, Lefkowitz R J
Endocrinology. 1976 Aug;99(2):347-57. doi: 10.1210/endo-99-2-347.
Injection of frogs with beta-adrenergic catecholamines produced a selective desensitization (loss of responsiveness) of the erythrocyte membrane adenylate cylase to subsequent stimulation in vitro by isoproterenol. Basal, prostaglandin E1- and fluoride-sensitive enzyme activities were unaffected. A 77% (p less than 0.001) decline in isoproterenol-responsive enzyme activity in the cells from the treated animals was observed with no change in the Km for isoproterenol stimulation of the enzyme (concentration causing 1/2 maximal enzyme activation). The decrease in catecholamine-sensitive adenylate cyclase was accompanied by a parallel 68% (p less than 0.001) fall in the apparent number of beta-adrenergic receptors in the erythrocyte membranes, assessed by (-) (3H)alprenolol binding studies. There was no change in the affinity of the receptor binding sites. The catecholamine-induced desensitization and fall in the beta-adrenergic receptor number were both concentration and time-dependent and displayed beta-adrenergic specificity. Isoproterenol was more potent in desensitizing cells and in lowering the receptor number than was norepinephrine. The beta-adrenergic antagonist propranolol, but not the alpha-adrenergic antagonist phentolamine, blocked the desensitizing effects of isoproterenol. Propranolol itself, however, did not cause desensitization. Cells became resensitized to the stimulatory effects of catecholamines, in association with a return in beta-receptor number, when propranolol was injected into previously desensitized animals. The changes in receptor number in membranes from desensitized and resensitized animals were also reflected in soluble receptor preparations. The protein synthesis inhibitor cycloheximide did not affect either desensitization, resensitization, or the changes in receptor number which accompanied the changes in adenylate cyclase sensitivity to catecholamines. These findings suggest that the chronic occupancy of beta-adrenergic receptors by beta-adrenergic agonists (but not antagonists) decreases the number of functional beta-adrenergic receptor binding sites and, hence, lowers the responsiveness of adenylate cylase to catecholamine stimulation. The lack of effort of cycloheximide on these regulatory effects suggests that "inactivation" and subsequent "reactivation" of the receptors, rather than changes in receptor turnover, are involved.
给青蛙注射β-肾上腺素能儿茶酚胺会使红细胞膜腺苷酸环化酶对随后异丙肾上腺素的体外刺激产生选择性脱敏(反应性丧失)。基础、前列腺素E1和氟化物敏感的酶活性不受影响。观察到处理过的动物细胞中异丙肾上腺素反应性酶活性下降了77%(p<0.001),而异丙肾上腺素刺激该酶的Km(引起最大酶激活一半的浓度)没有变化。儿茶酚胺敏感的腺苷酸环化酶的减少伴随着红细胞膜中β-肾上腺素能受体表观数量平行下降68%(p<0.001),这是通过(-)(3H)阿普洛尔结合研究评估的。受体结合位点的亲和力没有变化。儿茶酚胺诱导的脱敏和β-肾上腺素能受体数量的下降都是浓度和时间依赖性的,并且表现出β-肾上腺素能特异性。异丙肾上腺素在使细胞脱敏和降低受体数量方面比去甲肾上腺素更有效。β-肾上腺素能拮抗剂普萘洛尔,但不是α-肾上腺素能拮抗剂酚妥拉明,阻断了异丙肾上腺素的脱敏作用。然而,普萘洛尔本身不会引起脱敏。当将普萘洛尔注射到先前脱敏的动物中时,细胞会重新对儿茶酚胺的刺激产生敏感,同时β-受体数量会恢复。脱敏和重新致敏动物膜中受体数量的变化也反映在可溶性受体制剂中。蛋白质合成抑制剂环己酰亚胺既不影响脱敏、重新致敏,也不影响伴随腺苷酸环化酶对儿茶酚胺敏感性变化的受体数量变化。这些发现表明,β-肾上腺素能激动剂(而非拮抗剂)对β-肾上腺素能受体的长期占据会减少功能性β-肾上腺素能受体结合位点的数量,从而降低腺苷酸环化酶对儿茶酚胺刺激的反应性。环己酰亚胺对这些调节作用缺乏影响表明,涉及的是受体的“失活”和随后的“重新激活”,而非受体周转的变化。